On December 18, 2019 Seattle Genetics, Inc. (Nasdaq: SGEN) reported that it will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEVTM (enfortumab vedotin-ejfv) (Press release, Seattle Genetics, DEC 18, 2019, View Source [SID1234552522]). Access to the event can be obtained as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LIVE access on Thursday, December 19, 2019
6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time
Telephone 800-367-2403 (domestic) or +1 334-777-6978 (international); conference ID 7236397
Webcast available at www.seattlegenetics.com in the Investors section
REPLAY access
Telephone replay will be available beginning at approximately 9:00 a.m. PT on Thursday, December 19, 2019 through 9:00 a.m. PT on Sunday, December 22, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7236397
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section